SCHEMBL20720701

SCHEMBL20720701

COc1c(OCC2CCN(C)C2)cc2nc3ccccc3c(NC3CCOCC3)c2c1OC=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EHMT2 Q96KQ7 8/20 0.42
▸ DNMT1 P26358 1/20 0.37
▸ KCNH2 Q12809 2/20 0.37
▸ HTR4 Q13639 2/20 0.37
▸ EHMT1 Q9H9B1 5/20 0.36
▸ EGFR P00533 6/20 0.36
▸ KIT P10721 1/20 0.36
▸ MAOB P27338 1/20 0.36
▸ HTR6 P50406 1/20 0.36
▸ ABL1 P00519 1/20 0.36
▸ SRC P12931 1/20 0.36
▸ ABL2 P42684 1/20 0.36
▸ HDAC3 O15379 1/20 0.35
▸ APP P05067 1/20 0.35
▸ ACHE P22303 1/20 0.35
▸ HDAC4 P56524 1/20 0.35
▸ HDAC1 Q13547 1/20 0.35
▸ HDAC7 Q8WUI4 1/20 0.35
▸ HDAC2 Q92769 1/20 0.35
▸ HDAC8 Q9BY41 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formic Acid SCHEMBL19260567 0.84 EHMT2 (0.54) EHMT2DNMT1EHMT1EGFRKIT
SCHEMBL19260536 0.83 EHMT2 (0.58) EHMT2DNMT1EHMT1EGFRKIT
SCHEMBL20720607 0.82 EHMT2 (0.43) EHMT2DNMT1
SCHEMBL20720746 0.82 EHMT2 (0.43) EHMT2DNMT1
SCHEMBL20720734 0.80 EHMT2 (0.48) EHMT2DNMT1
SCHEMBL20720633 0.78 EHMT2 (0.42) EHMT2DNMT1HTR4
SCHEMBL20720732 0.78 EHMT2 (0.46) EHMT2DNMT1EHMT1SRC
SCHEMBL20720687 0.76 EHMT2 (0.43) EHMT2DNMT1
SCHEMBL20720703 0.75 EHMT2 (0.42) EHMT2DNMT1HTR4
SCHEMBL20720750 0.74 HDAC3 (0.40) EGFRKITABL1SRCABL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11254651-B2 Histone methyltransferase inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2022-02-22 — — US disclosed
EP-3416963-B1 HISTONE METHYLTRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS INC (US) 2021-07-28 — — EP disclosed
US-20190047981-A1 HISTONE METHYLTRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. 2019-02-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190047981-A1 HISTONE METHYLTRANSFERASE INHIBITORS EHMT1, EHMT2, BMI1 EHMT2 2/4885DNMT1 32/4885KCNH2 2770/4885
US-11254651-B2 Histone methyltransferase inhibitors EHMT1, EHMT2, BMI1 EHMT2 2/4885DNMT1 32/4885KCNH2 2770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback